美欧协议下药品关税悬而未决，分析师称或危及整个协议

Core Viewpoint - The uncertainty surrounding pharmaceutical tariffs in the US-EU agreement poses a risk to the entire trade deal, with significant implications for the pharmaceutical industry and the European economy [1] Pharmaceutical Industry Impact - Pharmaceutical products represent the largest category of EU exports to the US, with an estimated total export value of $120 billion in 2024 [1] - Analysts estimate that a 15% tariff could increase industry costs by $13 billion to $19 billion annually [1] - The Eurasia Group analysts warn that tariffs exceeding the 15% cap could jeopardize the entire trade truce [1] Economic Implications - Even if the tariff dispute does not undermine the overall agreement, the impact on the European economy could be severe [1]